Longeveron (LGVN) AI Stock Analysis

• Market Cap: $23.26M
• Dividend Yield: N/A
• Average Volume (3M): 600.14K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.71
• Revenue Growth: 127.51%
• EPS Growth: 71.16%
• Country: US
• Employees: 25
• Sector: Healthcare
• Sector Strength: 37
• Industry: Biotechnology
• EPS (TTM): -0.34
• Shares Outstanding: 13,525,301
• 10 Day Avg. Volume: 182,041
• 30 Day Avg. Volume: 600,136
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 0.44
• Enterprise Value/Revenue: 4.56
• Enterprise Value/Gross Profit: 5.54
• Enterprise Value/Ebitda: -0.60
• 1Y Price Target: $8.67
• Price Target Upside: 582.68% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3

• Rating: 56 Neutral
• Price Target: $1.50 ▲(18.11% Upside)

Longeveron's overall stock score is primarily influenced by its financial performance challenges and valuation concerns, which are offset by positive corporate developments such as the FDA approval for a new clinical trial. Technical indicators provide a mixed outlook, with some recent positive trends.

Positive Factors

Financial Support

The study is funded by a grant from the National Institute of Health, offsetting study expenses and providing financial support.

Regulatory Designations

Laromestrocel has Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation, which could expedite its approval process.

Regulatory Support

The FDA's ongoing commitment to streamlining approvals for rare diseases, particularly rare pediatric diseases, is expected to support the company's filing on a positive note.

Negative Factors

Financial Performance

Longeveron reported a net loss, and it is expected that the company will require additional capital.

Market Performance

Possible setbacks for Lomecel-B in other indications, notably Alzheimer's Disease, could impact market performance.

Trial Risks

Risks include the potential failure of Lomecel-B in the ELPIS-II trial of HLHS patients and inability to obtain regulatory approval.

Longeveron Business Overview & Revenue Model

Company Description

Longeveron Inc. is a biotechnology company focused on developing cellular therapies for aging-related and life-threatening conditions. The company is engaged in the research and development of regenerative medicine, specializing in the use of medicinal signaling cells (MSCs) derived from donor bone marrow. Longeveron aims to harness the potential of these cells to address medical conditions associated with aging, such as frailty, and other severe diseases, thereby improving patient outcomes and enhancing quality of life.

How the Company Makes Money

Longeveron primarily generates revenue through its clinical development programs, where it conducts clinical trials to evaluate the efficacy and safety of its proprietary cell therapies. The company may receive funding from government grants, research collaborations, and partnerships with other medical institutions to support its research initiatives. Additionally, Longeveron may earn revenue from licensing agreements if its therapies receive regulatory approval and are commercialized. The company's financial performance is significantly influenced by the progress of its clinical trials, regulatory milestones, and strategic partnerships that facilitate the advancement and potential commercialization of its therapies.

Longeveron Financial Statement Overview

Summary

Longeveron's financial performance is challenged by significant operational and profitability issues. The income statement reflects declining revenue and substantial losses with a negative net profit margin. The balance sheet shows low leverage and a strong equity base, but the negative ROE points to unprofitability. Cash flow issues are evident with negative free and operating cash flows, indicating financial instability despite strong financing inflows.

Income Statement

The company has been experiencing a decline in revenue with a negative revenue growth rate from $2,392,000 in 2024 to $2,225,000 in TTM. Gross profit margin is relatively strong at 82.3% in TTM, but the net profit margin is highly negative at -760.5%, indicating significant losses. EBIT and EBITDA margins are also negative, reflecting operational challenges. Overall, profitability is a significant concern.

Balance Sheet

The debt-to-equity ratio is 0.04 in TTM, indicating low leverage, which is a positive aspect. However, the return on equity is negative due to net losses. The equity ratio is 82.3%, indicating a strong equity base. While there are strengths in terms of low debt, the negative ROE points to unprofitability issues.

Cash Flow

There is a substantial negative free cash flow and operating cash flow, reflecting cash outflow issues. The free cash flow to net income ratio is close to 1, suggesting cash flow challenges are aligned with the company's net losses. Financing inflows have been strong, but sustainability is a concern given ongoing operational losses.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.39M	709.00K	1.22M	1.31M	5.63M
Gross Profit	1.88M	221.00K	497.00K	590.00K	1.83M
EBITDA	-16.52M	-20.06M	-17.15M	-16.18M	-2.93M
Net Income	-15.97M	-21.41M	-19.63M	-17.16M	-3.79M
Balance Sheet
Total Assets	25.56M	12.08M	27.41M	42.77M	9.24M
Cash, Cash Equivalents and Short-Term Investments	19.23M	5.36M	19.66M	35.04M	815.80K
Total Debt	1.45M	2.04M	2.60M	3.14M	4.14M
Total Liabilities	3.67M	5.34M	6.91M	5.31M	7.28M
Stockholders Equity	21.89M	6.74M	20.50M	37.45M	1.96M
Cash Flow
Free Cash Flow	-14.86M	-19.70M	-14.82M	-10.95M	-2.63M
Operating Cash Flow	-13.87M	-19.00M	-13.97M	-9.64M	-2.36M
Investing Cash Flow	-640.00K	8.19M	-677.00K	-10.70M	-261.50K
Financing Cash Flow	28.79M	5.26M	-509.00K	45.17M	1.58M

Longeveron Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.27
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LGVN, the sentiment is Negative. The current price of 1.27 is below the 20-day moving average (MA) of 1.57, below the 50-day MA of 1.40, and below the 200-day MA of 1.63, indicating a bearish trend. The MACD of 0.02 indicates Positive momentum. The RSI at 36.49 is Neutral, neither overbought nor oversold. The STOCH value of 9.13 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for LGVN.

Longeveron Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
LGVN	56 Neutral	$23.26M	―	-167.57%	―	127.51%	71.16%
OVID	54 Neutral	$35.29M	―	-36.31%	―	15.73%	51.00%
Sector *	51 Neutral	$7.39B	0.36	-62.86%	2.37%	15.48%	-2.68%
PASG	44 Neutral	$18.13M	―	-83.73%	―	―	42.39%
NNVC	42 Neutral	$25.55M	―	-99.84%	―	―	10.23%
CALC	39 Underperform	$41.92M	―	-134.15%	―	―	95.48%
CMMB	33 Underperform	$18.49M	―	-112.99%	―	―	57.93%

Longeveron Corporate Events

Longeveron Gains FDA Approval for Laromestrocel Trial

On July 8, 2025, Longeveron Inc. announced that the U.S. FDA has approved their Investigational New Drug application for laromestrocel, allowing the company to initiate a Phase 2 pivotal registration clinical trial for treating pediatric dilated cardiomyopathy (DCM). This approval marks a significant milestone in pediatric cardiovascular treatment, as current options are limited and often result in heart transplants or death for nearly 40% of affected children. The trial is expected to begin in the first half of 2026, and laromestrocel’s potential to repair damaged heart tissue could be groundbreaking for pediatric cardiovascular diseases.

The most recent analyst rating on (LGVN) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Longeveron stock, see the LGVN Stock Forecast page.

Longeveron Elects New Director at Annual Meeting

On June 13, 2025, Longeveron held its annual stockholders’ meeting where three key proposals were voted on. The stockholders elected Rock Soffer as a Class I director for a three-year term, approved an amendment to the 2021 Incentive Award Plan to increase authorized shares, and ratified CBIZ CPAs P.C. as the independent registered public accounting firm for fiscal 2025.

The most recent analyst rating on (LGVN) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Longeveron stock, see the LGVN Stock Forecast page.